A2i Therapeutics

Company Overview

Snapshot

Founded in November 2020, A2i Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from RMGP Biopharma Investment Fund and FutuRx. In November 2020, the company received a grant from the Israel Innovation Authority.

Business overview

A2i Therapeutics develops novel small-molecule immuno-oncology agents, leveraging artificial intelligence for drug discovery. The company focuses on targeting key proteins involved in controlling the innate immune response, which are potential immuno-oncology targets. Operating within the Health Tech & Life Sciences sector, A2i Therapeutics serves the pharmaceutical industry with its biotechnology and drug discovery solutions.

Strategic signal

In December 2020, A2i Therapeutics launched as a joint venture between FutuRx and Atomwise, signaling a strategic collaboration to combine Atomwise's AI platform with FutuRx's incubator model for innovative therapeutic technologies. This partnership highlights a growing trend of integrating AI into early-stage drug discovery, aiming to accelerate the development of immuno-oncology agents and offering a validation of AI's role in biopharmaceutical innovation.

Company Intelligence Q&A

What is A2i Therapeutics' primary focus?

A2i Therapeutics is focused on developing novel small-molecule immuno-oncology agents, utilizing artificial intelligence for drug discovery.

When was A2i Therapeutics founded?

A2i Therapeutics was founded in November 2020.

What significant event occurred in November 2020?

In November 2020, A2i Therapeutics received a grant from the Israel Innovation Authority.

Which investors participated in A2i Therapeutics' funding round in November 2020?

In November 2020, A2i Therapeutics received funding from RMGP Biopharma Investment Fund and FutuRx.

What is the status of A2i Therapeutics?

A2i Therapeutics is currently non-active, having ceased to operate in July 2026.